As on :
05-Aug-26 19:09
FDC Limited (NSE: FDC, BSE: 531599) announced its unaudited financial results for the first quarter ended June 30, 2026, reporting consolidated revenue from operations of Rs. 668 crore, a 3.0% year-over-year increase compared to Rs. 648 crore in the same quarter of the previous year, driven primarily by the performance of International Formulations, particularly the US business, while Domestic Formulations and APIs remained relatively muted. The company also received U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL during the quarter.
